Storage Stability
Prodynorphin (PDYN) is the ~29 kDa opioid precursor polypeptide that is processed to yield multiple active kappa-opioid peptides including dynorphin A (1-17), dynorphin B (1-13), alpha-neoendorphin, beta-neoendorphin, and leumorphin. Each fragment has distinct receptor selectivity and potency profiles.
Mechanism of Action
- Tissue-specific proteolytic processing by PC1/PC2 prohormone convertases yields 7+ distinct bioactive opioid peptides
- Dynorphin A (1-17): high-affinity KOR agonist; produces dysphoria, analgesia, and stress responses
- Alpha-neoendorphin: mixed KOR/mu-OR activity; analgesic
- Prodynorphin is upregulated in dorsal horn neurons during chronic pain, contributing to central sensitization via KOR signaling
- Prodynorphin gene expression regulated by CRH, glucocorticoids, and D1 dopamine receptor signaling in striatum
Research Findings
- PDYN gene variants associated with alcohol dependence, schizophrenia, and opioid addiction vulnerability in GWAS studies
- Prodynorphin upregulation in spinal cord during neuropathic pain; KOR antagonists (JDTic, aticaprant) tested for analgesic/antidepressant effects
- Spinocerebellar ataxia type 23 linked to missense mutations in PDYN causing gain-of-function neurotoxic dynorphin fragments
- PDYN knockout mice show reduced tolerance to opioids and altered stress responsivity
- Dynorphin A (2-17) lacking opioid activity still produces neurotoxic effects via NMDA receptor, suggesting dual mechanisms
Research Protocols
- Dynorphin A (1-17) research peptide: 1-10 mg/kg IP or SC in rodent pain models (KOR agonist reference standard)
- Intrathecal dynorphin A: 3-10 nmol in rodents for spinal cord KOR effects and hyperalgesia studies
- KOR antagonist studies: PDYN overexpressing transgenic mice as depression/stress models
- Plasma/CSF prodynorphin fragment measurement by ELISA for biomarker studies in pain/addiction
Interactions
- KOR antagonists (aticaprant, JDTic): block dynorphin A-mediated dysphoria and stress-induced analgesia
- Naloxone/naltrexone: partially block dynorphin effects at lower affinity vs mu-opioid
- CRH/CRF: co-released with dynorphin in stress circuits; corticotropin axis cross-regulation
Safety Profile
Prodynorphin itself not therapeutic. Active dynorphin A fragments are research tools. KOR agonism produces sedation, dysphoria, and psychotomimetic effects; KOR antagonists derived from this pathway are in Phase II for depression and alcohol use disorder.
Legal & Regulatory
Research peptide; not approved as therapeutic
Ready to dose Prodynorphin?
Get the exact syringe draw
You have read the research. Now run the math. Pick your vial size and BAC water volume, get IU draw in seconds.
Open the Calculator →
More in Cognitive & Mood
View all →